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Abstract 
This report summarizes the proceedings of the 4th European Bone Sarcoma Networking Meeting, held in London, 
England, on 21 June 2017. The meeting brought together scientific and clinical researchers and representatives from 
sarcoma charities from 19 countries representing five networks across Europe, to present and discuss new develop‑
ments on bone sarcoma. In view of the challenges is poses, the meeting focussed primarily on osteosarcoma with 
presentations on developments in our understanding of osteosarcoma genetics and immunology as well as results 
from preclinical investigations and discussion of recent and ongoing clinical trials. These include studies examining 
the efficacy of multi‑targeted tyrosine kinase inhibitors and checkpoint inhibitors, as well as those with molecular 
profiling to stratify patients for specific therapies. Discussion was centred on generation of new hypotheses for col‑
laborative biological and clinical investigations, the ultimate goal being to improve therapy and outcome in patients 
with bone sarcomas.
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Introduction
The 4th European Bone Sarcoma Networking meeting 
brought together scientific and clinical researchers and 
representatives from sarcoma charities, from 19 coun-
tries representing five networks across Europe to discuss 
the latest developments in bone sarcoma research. This 
builds on the successful previous meetings [1]. Since 
the closure of the EURAMOS-1 trial in 2011 there have 
been no international phase III studies open for Euro-
pean patients with osteosarcoma. In view of this ongoing 
unmet need, the meeting focussed primarily on this chal-
lenging disease. The meeting opened with presentations 
from National Study Groups on current clinical trials 
as well as those in development, including a number of 
immunotherapy-based trials. Potential therapies based 
on recent osteosarcoma genetic studies and subsequently 
immunology and immunotherapy were discussed as well 
as the role for biomarkers both to identify patients for 
these studies and for monitoring of disease.
Current national study programmes
The first session was an opportunity for national study 
groups to present recent clinical trials that have recruited 
patients with osteosarcoma, are currently recruiting 
osteosarcoma patients or are under development (sum-
marised in Table 1). The Spanish Group for Research on 
Sarcoma (GEIS) represented by Nadia Hindi, presented 
data from GEIS 29 trial, a phase II trial on the combi-
nation of gemcitabine and sirolimus [2]. In this study, 
patients with advanced pretreated osteosarcoma received 
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up to six cycles of gemcitabine 800 mg/m2 days 1 and 8 
and Sirolimus (5  mg per day) in a continuous regimen 
(except the day before and the day of infusion of gem-
citabine). The trial was positive for its primary endpoint, 
with a 4-month PFS rate of 44%. Median PFS and OS 
were 2.3 and 7.1 months respectively. Expression of Ribo-
nucleotide Reductase catalytic subunit 1 (RRM1) was 
related with a worse outcome, both in terms of PFS and 
OS [2]. The GEIS group has another two phase II trials 
actively recruiting patients with advanced osteosarcoma: 
GEIS 51 (Palbosarc), which is examining the role of the 
CDK4 inhibitor palbociclib in patients with osteosar-
coma or soft tissue sarcoma overexpressing CDK4 and 
GEIS 52 (InmunoSARC), which is examining the toler-
ance and efficacy of the combination of sunitinib and 
nivolumab in patients with bone and soft tissue sarcomas 
[3, 4].
Nathalie Gaspar, on behalf of The French bone 
sarcoma group presented the upcoming French 
Sarcome13/0S2016 trial. This is a first-line randomised 
Phase-2 trial of mifamurtide (MEPACT ®) combined 
with post-operative chemotherapy for newly diagnosed 
patients up to the age of 50  years with high risk osteo-
sarcoma (metastatic or localized disease with poor 
histologic response to neoadjuvant chemotherapy). Sar-
come13/OS2016 backbone chemotherapy is based on 
Table 1 Recent European clinical trials recruiting patients with osteosarcoma
NA not available
Trial name Title/description Country Study reference
GEIS 29 Multicenter and prospective phase II trial 
with gemcitabine and rapamycin in sec‑
ond line of metastatic osteosarcoma
Spain NCT02429973
GEIS 51 (Palbosarc) Phase II multicenter trial of palbociclib in 
second line of advanced sarcomas with 
CDK4 overexpression
Spain NCT03242382
GEIS 52 (InmunoSARC) Phase I–II trial of sunitinib plus nivolumab 
after standard treatment in advanced soft 
tissue and bone sarcomas
Spain, Italy NCT03277924
Sarcome13/0S2016 Randomised phase‑2 trial of mifamurtide 
(MEPACT ®) combined with post‑operative 
chemotherapy for newly diagnosed 
patients up to 50 years with high risk 
osteosarcoma (metastatic or localized 
disease with poor histologic response to 
neoadjuvant chemotherapy).
France NA
Regobone A phase II study evaluating efficacy and 
safety of regorafenib in patients with 
metastatic bone sarcomas
France NCT02389244
Cabone Cabozantinib‑s‑malate in treating patients 
with relapsed osteosarcoma or Ewing 
sarcoma
France NCT02243605
HOPE ITCC‑035 Study of lenvatinib in children and ado‑
lescents with refractory or relapsed solid 
malignancies and young adults with 
osteosarcoma
France, USA, Germany, Italy, Spain, UK NCT02432274
PembroSARC Combination of MK3475 and metronomic 
cyclophosphamide in patients with 
advanced sarcomas: multicentre phase 
II trial
France NCT02406781
PROMO A phase II study of pembrolizumab in 
patients with relapsed or metastatic osteo‑
sarcoma not eligible for curative surgery
Norway, Italy NCT03013127
MAPPYACTS Proof‑of‑concept study to stratify targeted 
therapies adapted to molecular profiling
France, Ireland, Israel, Italy, Spain NCT02613962
ESMART European proof‑of‑concept therapeutic 
stratification trial of molecular anomalies 
in relapsed or refractory tumors
France, Germany, Italy, Netherlands, Spain, 
UK
NCT02813135
Can cancer cells be found in blood 
samples from patients with bone 
sarcoma?
Enumeration of circulating tumour cells in 
patients with bone sarcomas: an observa‑
tional study
UK ISRCTN29619083
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the previous, Unicancer sponsored, French OS2006/
Sarcome9 trial (M-EI in children, adolescent and young 
adults and API-AI in adults) [5, 6]. Post-operative mifa-
murtide administration for 36  weeks, is randomised in 
addition to post-operative chemotherapy. This rand-
omized trial, the first since the controversial INT-033 
trial, is using a Bayesian design to determine whether 
the macrophage modulator, mifamurtide, provides ben-
efit to this group of patients [7]. Several phase-2 tri-
als for relapsed osteosarcoma patients are on-going in 
France testing different multi-tyrosine kinase inhibitors 
alone, either randomized versus placebo (Regobone from 
10 years old), or in single arm phase-2 trial (Cabone from 
12  years old), as well as associated with chemotherapy 
(HOPE, ITCC-035, lenvatinib ± etoposide/ifosfamide 
up to 25  years old) [8–10]. Recent international stud-
ies investigating immune check point inhibitors (anti-
PD1 and anti-PDL1), alone have not been as promising 
as hoped and further work is required to understand 
mechanisms of resistance and which patients are likely to 
respond to these agents [11, 12]. Results of a combination 
French study with metronomic cyclophosphamide are 
awaited (PembroSARC) [13]. The next trial for paediatric 
and adult patients with osteosarcoma relapse is being dis-
cussed within the ITCC Consortium (Innovative Thera-
pies for Children with Cancer) and consideration is being 
given to combination of two promising approaches, a 
multi-tyrosine kinase inhibitor and an immune modula-
tor. Inclusion of osteosarcoma with molecular profiling in 
the multiarm phase-1/2 trial AcSé-eSMART ITCC-057 
provides an opportunity to investigate the activity of a 
PARP inhibitor in combination with irinotecan or WEE1 
inhibitor with carboplatin [14].
Elisa Tirtei, Turin, on behalf of The Italian Sarcoma 
Group presented a study that opened in November 2016 
and is a collaboration with the Italian Onco-Haematology 
Paediatric Association (AIEOP) and Italian Institute for 
Genomic Medicine of Turin. It is a prospective, multicen-
tre study to analyse the tumour genomic profile of paedi-
atric and adult patients with new diagnoses of sarcoma 
or relapsed/refractory sarcoma. By comparing tumour 
samples with the corresponding non-tumour tissue (e.g. 
peripheral blood), the aim of the study is to define the 
genomic profile of each sample taking advantage of a 
next generation sequencing (NGS) platform. A panel of 
410 genes to analyse using the Illumina technique have 
been chosen. Furthermore, starting from fresh sarcoma 
samples obtained from surgical biopsies, the group aim 
to establish in vitro cultures and in vivo patient-derived 
xenografts (PDX) to generate working models. To date, 
the study has recruited nine patients and has demon-
strated the feasibility of this approach. It will now expand 
to all paediatric Italian oncology departments, so all 
patients could benefit from precision medicine and it will 
be an opportunity to widen preclinical research studies 
about sarcomas.
The UK National Cancer Research Institute (NCRI) 
Bone Sarcoma Clinical Studies Group aims to develop 
UK National Institute Health Research (NIHR) portfolio 
studies in primary bone tumours. Sandra Strauss, Lon-
don, presented two studies in osteosarcoma, the first, is 
a prospective cohort study of patients with newly diag-
nosed osteosarcoma that aims to (i) describe the expe-
rience, treatment and outcomes of patients of all ages 
in the UK; (ii) to investigate the impact of tumour het-
erogeneity and tumour evolution on patient outcome 
through the collection of biological samples; (iii) to vali-
date biomarkers to accelerate selection of patients with 
high risk disease into Phase Ib/II clinical trials; (iv) to 
identify factors influencing decisions about local therapy 
and outcomes. She also outlined a multicenter observa-
tional study lead by Kenny Rankin, Newcastle evaluating 
the potential of using MT1-MMP1 to isolate circulating 
tumour cells (CTCs) in patients with osteosarcoma at 
diagnosis and subsequent treatment stages. To date the 
study has recruited 30 patients across four sites [15].
The session concluded with a presentation by Jakob 
Anninga, Nijmegen, of a study investigating the effect 
of dose-intensity on event-free survival (EFS) in groups 
of patients with localized osteosarcoma. Clinical data 
from MRC BO06 was used to perform a landmark analy-
sis, which aimed to cluster patients on the similarity of 
the individual received dose-intensity (iRDI). The group 
demonstrated a more accurate relationship between 
iRDI and EFS when investigated by the whole individual 
treatment-history, i.e. using longitudinal treatment-data, 
compared to using either intention-to-treat analysis or 
just the final value of iRDI. Their results suggest that indi-
vidual tolerability is an important issue in EFS and that 
maintenance of treatment intensification towards an 
individual’s biological tolerance is beneficial.
Genetic targets in osteosarcoma
A number of presentations focused on recent data gen-
erated from sequence analyses performed in osteosar-
coma, with identification of potential genetic targets and 
a discussion of the clinical implications of these find-
ings. Sam Behjati, Cambridge, presented findings of the 
osteosarcoma study of the International Cancer Genome 
Consortium. In that analysis, 112 childhood and adult 
tumours, encompassing all major histological subtypes, 
were studied by whole exome (n = 75) or whole genome 
sequencing (n = 37). In 32/112 cases an actionable muta-
tion was identified, including 20 cases with amplifica-
tions of receptor tyrosine kinases. Amongst these were 
amplifications of IGF1R that occurred in ~ 10% of cases, a 
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finding that was validated by FISH in an extension cohort 
of 87 cases. Overall the findings of this study provide a 
rationale for a basket trial in osteosarcoma that focuses 
on actionable mutations, including amplifications of the 
IGF1R gene [16].
Daniel Baumhoer, Basel, presented the findings of a 
whole exome sequence analysis of 31 osteosarcomas, 
which demonstrated that these tumours show highly 
complex karyotypes with abundant structural and 
numerical aberrations and a multitude of different driver 
genes. However, despite the great amount of inter- and 
intratumoural heterogeneity, in their analysis, the major-
ity of tumours (> 85%) appear to acquire a deficiency 
in homologous recombination (HR) repair that could 
potentially be therapeutically exploited by using PARP-
inhibitors [17]. It is well recognized that PARP-inhibitors 
are effective in tumours harbouring deleterious germline 
or somatic mutation in BRCA1/2, i.e. breast and ovar-
ian cancer, as shown by many studies [18]. Patients with 
wild-type BRCA who have a homologous recombination 
deficiency (“BRCAness”) have also been shown to be sen-
sitive to PARP inhibition [19] as well as platinum-based 
chemotherapy [20]. He presented pre-clinical data on the 
efficacy of PARP-inhibitors in reducing cell viability oste-
osarcoma cell lines, which has been demonstrated by a 
number of groups [21]. He concluded on the basis of this 
evidence, that although there is no universally accepted 
test to assess the sensitivity of tumours to this treatment 
(so-called “BRCAness”) in patients upfront, there is a 
molecular rationale to try this approach also in patients 
ideally within the framework of a clinical study.
Accurate methods to detect HR-deficiency in clini-
cal samples to identify the patients that can benefit from 
these treatments are highly sought and a number are 
under development. Andrea Degasperi, Cambridge, pre-
sented a novel method to predict BRCA1 and BRCA2 
deficiency based on mutational signatures, called HRDe-
tect, which is a classifier that identifies tumours with 
a specific type of HR defect—BRCA1 or BRCA2 defi-
ciency in particular [22]. HRDetect was trained on whole 
genome sequenced (WGS) breast cancers and validated 
on independent cohorts of breast, ovarian and pancre-
atic cancers. This classifier is currently the most accurate 
method for predicting BRCA1 or BRCA2 deficiency in 
such tumours (AUC ~ 0.98) [22]. However, when applied 
to osteosarcomas in the ICGC data set, HRDetect pre-
dicted that only one sample of the 37 WGS samples 
tested was similar to BRCA1/BRCA2-deficient breast 
cancers. Although HRDetect has not yet been validated 
in osteosarcoma, due to the rarity of BRCA1/BRCA2 
deficient bone tumours, this result indicates that BRCA1/
BRCA2 deficient-like tumours may not be very common 
in osteosarcoma and need to be carefully stratified for 
appropriate treatment. At the same time, other types of 
HR deficiency may be present in osteosarcoma, that do 
not resemble BRCA1/BRCA2 deficiency in breast cancer. 
These results indicate that distinguishing patients with 
the various forms of genomic instability is not only pos-
sible, it is critical.
Ola Myklebost, Oslo, presented studies of the sensitiv-
ity of the EuroBoNet osteosarcoma cell line panel to the 
PARP inhibitor, Talazoparib [23]. The cell lines had vari-
able responses, from similar to that of the highly sensi-
tive BRCA-mutated breast cancer cell line SUM149 to 
that of the insensitive control HeLa, and responses of the 
osteosarcoma lines were long-lasting when the drug was 
removed. Various biomarkers were investigated, includ-
ing mutations in HRR genes, presence of SNV mutation 
profile 3, and the sensitivity to platinum drugs. None of 
these were strongly predictive, but the response to oxali-
platin performed best, with the response being confirmed 
in vivo in a mouse PDX model. A trial was proposed to 
investigate predictive markers, including the potential of 
the highly variable whole genome profiles.
Michaela Nathrath, Munich, representative of the 
Cooperative Osteosarcoma Study Group’s biology panel, 
also summarised the case for studying PARP inhibi-
tors in osteosarcoma based on the above evidence of 
Kovac et al. [17] and data from cell lines suggesting that 
BRCA-like phenotype is a unifying trait in osteosar-
coma. She suggested that the synthetic lethality concept 
using this BRCAness might be a new effective therapeu-
tic approach in osteosarcoma but also discussed that 
optimal techniques to select the patients who are likely 
to respond to PARP inhibitors have still to be defined 
and also that understanding drug resistance to PARP 
inhibitors is important. Despite these challenges, a 
multi-center Phase-II study with a PARP inhibitor com-
bined with chemotherapy including biomarker positive 
relapsed osteosarcoma patients is planned in Heidelberg/
Germany.
The session concluded with a discussion on the evi-
dence presented for the potential role for PARP inhibi-
tors in osteosarcoma. It was agreed that a number of 
questions remain outstanding, including the challenges 
of conducting a clinical trial without an optimal bio-
marker; that PARP inhibitors are most likely to be of 
benefit in combination with cytotoxic agents but that the 
optimal combination is presently unknown. It was also 
felt the osteosarcoma community may not have exploited 
the value of tyrosine kinase inhibitors (TKIs) in osteo-
sarcoma yet and that benefit in selected patients may 
have been hidden in previous studies. Discussions cov-
ered whether the recent data from Sam Behjati was suf-
ficient to consider further biomarker-driven studies using 
appropriate TKIs.
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Immunotherapy rationale, targets and other 
studies
S. Rubina Baglio, Amsterdam, discussed the results 
of her investigation on the local inflammation of the 
tumour microenvironment induced by osteosarcoma 
tumour cells. In a xenograft mouse model of osteosar-
coma, the research group demonstrated that the tumour 
cells release extracellular vesicles (EVs), carrying a mem-
brane-bound form of TGFβ, that “educate” mesenchymal 
stem cells to support tumour growth and lung metasta-
sis formation. This effect was caused by a switch in the 
mesenchymal stem cell cytokine expression profile, and 
could be fully revoked by the administration of the IL-6 
receptor antibody tocilizumab [24]. These findings pro-
vide a rationale for novel therapeutic strategies based on 
immunomodulatory drugs for osteosarcoma patients. In 
addition, the research group found evidence of increased 
levels of EV-bound TGFβ in the circulation of osteosar-
coma patients, which might provide an option for min-
imally-invasive therapy response monitoring with liquid 
biopsies. She concluded that the tumour ‘educated’ mes-
enchymal stem cells might modulate a local immunosup-
pressive niche, which could be targeted to stop tumour 
progression.
Kjetil Boye, Oslo, presented the PROMO-study, which 
commenced in May 2017, and will be carried out in col-
laboration with Bologna, Italy. This is a non-randomized, 
investigator-initiated phase-II study with pembrolizumab 
monotherapy for patients with metastatic, unresectable 
osteosarcoma. The study has a 2-stage design, and the 
primary endpoint is clinical benefit rate (SD+PR+CR) 
at 18  weeks using RECIST v1.1. Secondary endpoints 
include progression-free survival (PFS), overall response 
rate and duration of response evaluated by RECIST 
and immune-related response criteria, response by 18F-
FDG PET/CT, overall survival, safety and health-related 
quality of life. A total of 25 patients are expected to be 
included in the study.
Anne-Marie Cleton-Jansen, Leiden, presented a study 
of the expression of HLA and PD-L1 as well as the pres-
ence of infiltrating lymphocytes in a series of 87 primary 
osteosarcomas and metastases from 26 patients, to estab-
lish whether immunotherapy could be beneficial to meta-
static and chemotherapy refractory osteosarcoma. T cell 
infiltrate and PD-L1 expression increased during disease 
progression, suggesting that T-cell based immunotherapy 
with adoptive cell transfer, peptide vaccines or check-
point blockade could be a suitable approach for meta-
static osteosarcoma patients. Down regulation of HLA-A 
molecules may be a limiting factor, but only in a small 
fraction of the patients [25].
Elisa Tirtei, Turin, presented the outline of a phase-
I trial for the infusion of autologous, cytokine induced 
killer (CIK) cells in patients with advanced and/or refrac-
tory sarcoma. These cells were ex vivo expanded, HLA-
unrestricted T-/NK-cells, with NKG2D and MIC A/B as 
anti-tumour targets [26, 27]. In vitro studies in mice have 
shown significant tumour cell killing using this method.
The results of a French study to characterize the micro-
environment in the biopsies of 126 patients was pre-
sented by Francoise Rédini, Nantes. The French phase 
3 trial (OS 2006) testing the combination of  Zometa® 
with chemotherapy and surgery did not improve the 
outcome of patients with osteosarcoma. The authors 
studied the presence of infiltrating immune cells (CD68/
CD163 tumour-infiltrating macrophages, CD8 lym-
phocytes, osteoclasts, and the PD1/PDL-1 checkpoint) 
in the biopsies of patients who participated in the OS 
2006 trial. It was shown that high CD163 levels signifi-
cantly correlated with greater overall survival and with 
longer metastasis PFS independently of diagnosis sta-
tus. CD8 staining was positive in > 50% of cases with a 
median staining of 1%. Lower CD8 levels were associated 
with metastatic disease at diagnosis and only the pres-
ence of CD8-positive cells significantly correlated with 
improved overall survival in patients who were treated 
with the bisphosphonate  Zometa®. It was concluded that 
immunohistochemical analysis of the microenvironment 
in osteosarcoma patient biopsies could represent a novel 
tool for therapeutic stratification.
Katia Scotlandi, Italy, presented the results of a study 
of the effect of Trabectedin on the differentiation and 
immune environment in a murine osteosarcoma model. 
Of the two models, mOS13 formed smaller tumours, had 
an increased bone matrix deposition and a lower meta-
static deposition than mOS69 [28]. In the more differen-
tiated tumours a higher monocyte/macrophage  (CD68+), 
leucocyte  (CD45+) and lymphocyte  (CD4+/CD8+) infil-
tration was demonstrated. Results in patient samples 
showed a better survival in subjects that had high levels 
of cytotoxic T-cells  (CD8+/Tia1+: long term cumulative 
survival 81%, versus 45% in patients who were  CD8−/
Tia−) [29]. PD-L1 was positive in 14% of the patients, and 
had a worse survival in a subset with a  CD8+ infiltrate. 
In murine osteosarcoma, Trabectedin inhibited tumour 
growth and metastasis formation, affected gene-tran-
scription via RUNX2 activation to a more differentiated 
phenotype, and also induced the recruitment/expansion 
of adaptive T cells. However, analysis of tumour-infiltrat-
ing T cell phenotype and activation state from trabect-
edin-treated mice showed increased PD-1 checkpoint 
inhibitor expression on CD8 T cells, compatible with 
their impaired function. It was concluded from this study 
that Trabectedin reprogrammed the tumour associated 
micro-environment, providing the foundation for combi-
nation therapies with immune checkpoint inhibitors.
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Bone sarcomas and especially osteosarcomas are 
highly heterogeneous. This heterogeneity both between 
tumours (inter-tumour heterogeneity) and within 
tumours (intra-tumour heterogeneity) can be related to 
genetic and non-genetic factors and introduces signifi-
cant challenges for classifying patients that might benefit 
from targeted therapies. It has been suggested that CTCs 
may reflect the biological evolution (e.g. new mutation 
events) of primary tumours and associated metastases. 
Unfortunately, in contrast to carcinomas, in which CTCs 
have been isolated from epithelial markers (e.g. EpCAM), 
there are no specific markers expressed by sarcoma cells. 
However, sarcoma cells like other cancer cells frequently 
show a differential size compared to normal cells and a 
lower deformability. Size and deformability criteria have 
been used in pre-clinical models for isolating CTCs and 
could serve as proof-of-concept for pilot clinical trials in 
bone sarcoma [30]. Dominique Heymann, Sheffield, pre-
sented a pilot study that is using the Parsortix™ System 
to enrich for CTCs, which are then isolated and captured 
using the DEPArray™ System.
Finally, Michel Vanden Eynden, Belgium, presented a 
project investigating telomere maintenance in paediatric 
tumours, with a focus on osteosarcoma. Most cancers 
(85–90%) are known to reactivate telomerase to achieve 
cellular immortalisation [31]. However, another mecha-
nism, based on homologous recombination between 
telomeric sequences, called alternative lengthening of 
Telomeres (ALT), is also able to provide cells with indefi-
nite replication potential. It has been shown that  ALT+ 
cells are characterized by the presence of a more relaxed 
telomeric chromatin that may account for the elevated 
rates of telomeric sister chromatid recombinations typi-
cally found in these cells [32, 33]. ALT is known to be 
found mainly in paediatric tumours, with about 50% of 
osteosarcoma showing ALT features [34]. At present, 
understanding ALT mechanism is a major challenge; as 
it is absent from normal somatic cells, it represents an 
attractive target for cancer therapy, but specific inhibitors 
have not been identified yet. To better understand this 
mechanism and assess its relevance as a new prognostic 
biomarker or a new target for therapy, a collaboration 
with all paediatric oncology departments of university 
hospitals across Belgium has been created, which will 
allow tumour collection all across Belgium and further 
investigation on ALT in paediatric cancers.
Future networking
The meeting concluded with a discussion on role of 
future networks for osteosarcoma and commitment 
to support networking opportunities as being integral 
to facilitate collaboration and thereby improve out-
comes for patients. Opportunities for this lie within 
newly-developed European Reference Networks (EURA-
CAN/PaedCan), which aim to increase access of patients 
to specialist care and are currently focusing on develop-
ing clinical practice guidelines, training dissemination 
and determining how shared data collection could ben-
efit improvements in care for rare diseases [35]. It was 
also noted that SIOP Europe was in advanced planning 
of a clinical forum bringing together specialists from 
all tumour types affecting children and young people 
to allow cross cutting interdisciplinary work. This first 
Annual Meeting of the European Society for Paediatric 
Oncology, to be held May 20–25, 2019 in Prague, Czech 
Republic, is likely to represent a good opportunity to sus-
tain collaborative working between bone tumour experts.
Conclusion
Osteosarcoma is a challenging disease with little 
improvement in survival for three decades. To further 
improve outcomes, international collaboration propelled 
by initiatives like the European Bone Sarcoma Network 
is essential. Novel insights from studies on genomics, 
altered signalling pathways and sarcoma immunology as 
well as biomarkers to identify patients for clinical trials 
and to monitor disease were discussed. These built on 
presentations from previous meetings and included dis-
cussion about potential clinical trials, which now need to 
be taken forward to develop proposals for national and 
for collaborative research and trials.
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